We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Novozymes to Showcase cGMP-grade Hyaluronic Acid at CPhI 2011

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Novozymes to Showcase cGMP-grade Hyaluronic Acid at CPhI 2011"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Novozymes Biopharma will showcase its soon to be launched Q7 cGMP-grade hyaluronic acid (HA) at CPhI Worldwide 2011.

The new Bacillus-derived HA has been developed to improve how customers process and formulate HA for medical device and pharmaceutical applications, helping to speed up product development and creating improved therapeutics.

The product confers a range of unique performance advantages for medical devices, drug delivery and formulation and will be showcased on booth #42H55 in hall 4.2 at the Messe Frankfurt, October 25-27, in Frankfurt, Germany.

“Novozymes is delighted to be returning to CPhI to showcase the company’s soon to be launched Q7 cGMP HA”, comments Hans Ole Klingenberg, global marketing director at Novozymes.

Klingenberg continued, “Delegates will be able to see the HA and our team of experts will be on hand to provide insight into how it can be incorporated into their manufacturing processes to reduce testing time, save on manufacturing costs and take products to market faster.”

Novozymes’ HA has been developed to expand opportunities for HA across multiple applications in the pharmaceutical and medical device industries.

Produced at Novozymes’ new facility in Tianjin, China, which has been designed exclusively for HA, the company uses a patented water based process which is run in compliance with ICH Q7 cGMP guidelines.

The resulting HA is free of animal derived components and organic solvents, resulting in a high degree of purity and reduced risk of contamination.

It offers high batch-to-batch consistency with tight control of molecular weight for improved formulation control, as well as the capability to dissolve up to five times faster than other commercially available sources of HA.

In addition, superior heat stability permits autoclaving without significant loss of product viscosity.

The new HA can be customized further using Novozymes’ proprietary cross linking technology to achieve a specified viscosity, allowing the product to be adapted for a range of drug delivery and medical device applications.

From ophthalmology and dermal filling to osteoarthritis treatments and cancer treatment, the unique technology will assist customers to create improved therapeutics with real benefits for both manufacturers and patients.